Combination therapy versus single agent chemotherapy in non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1693-1700

  Cheong, Kerry ^a   Spicer, James ^a   Chowdhury, Simon ^a   Harper, Peter ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Lung cancer

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; VINDESINE;

AGE; ALOPECIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FITNESS; FUNCTIONAL ASSESSMENT; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; QUALITY OF LIFE; REVIEW; SYMPTOM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE;

EID: 23844510625     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1693     Document Type: Review

References (50)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br. Med. J. (1995) 311(7010):899-909.
2. ANDERSON H, HOPWOOD P, STEPHENS RJ et al.: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. Br. J. Cancer (2000) 83(4):447-453.
3. ROSZKOWSKI K, PLUZANSKA A, KRZAKOWSKI M et al.: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer (2000) 27(3):145-157.
4. RANSON M, DAVIDSON N, NICOLSON M et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (2000) 92(13):1074-1080.
5. SHANAFELT TD, LOPRINZI C, MARKS R, NOVOTNY P, SLOAN J: Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J. Clin. Oncol. (2004) 22(10):1966-1974.
6. LILENBAUM RC, LANCENBERG P, DICKERSIN K: Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer (1998) 82(1):116-126.
7. CULLEN MH, BILLINGHAM LJ, WOODROFFE CM et al.: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. (1999) 17(10):3188-3194.
8. PERNG RP, CHEN YM, MING-LIU J et al.: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J. Clin. Oncol. (1997) 15(5):2097-2102.
9. MANEGOLD C, BERGMAN B, CHEMAISSANI A et al.: Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. (1997) 8(6):525-529.
10. VANSTEENKISTE JF, VANDEBROEK JE, NACKAERTS KL et al.: Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann. Oncol. (2001) 12(9):1221-1230.
11. LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patienrs. J. Clin. Oncol. (1994) 12(2):360-367.
12. NEGORO S, MASUDA N, TAKADA Y et al.: Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer (2003) 88(3):335-341.
13. SEDERHOLM C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group. Proc. Am. Soc. Clin. Oncol. (2002) 21:1162.
14. LILENBAUM RC, HERNDON JE 2nd, LIST MA et al.: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J. Clin. Oncol. (2005) 23(1):190-196.
15. GEORGOULIAS V, ARDAVANIS A, AGELIDOU A et al.: Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J. Clin. Oncol. (2004) 22(13):2602-2609.
16. WOZNIAK AJ, CROWLEY JJ, BALCERZAK SP et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. (1998) 16(7):2459-2465.
17. SANDLER AB, NEMUNAITIS J, DENHAM C et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2000) 18(1):122-130.
18. GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al.: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2000) 18(19):3390-3399.
19. DELBALDO C, MICHIELS S, SYZ N et al.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA (2004) 292(4):470-484.
20. BAGGSTROM M, SOCINSKI M, HENSING T, POOLE C: Addressing the optimal number of cytotoxic agents in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc. Am. Soc. Clin. Oncol. (2003) 22:624.
21. SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346(2):92-98.
22. COMELLA P, FRASCI G, PANZA N et al.: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J. Clin. Oncol. (2000) 18(7):1451-1457.
23. LE CHEVALIER T, SCAGLIOTTI G, NATALE R et al.: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 47(1):69-80.
24. HOTTA K, MATSUO K, UEOKA H et al.: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(19):3852-3859.
25. RUDD RM, GOWER NH, SPIRO SG et al.: Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. (2005) 23(1)142-153.
26. GEORGOULIAS V, SAMONIS G, PAPADAKIS E et al.: Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer (2001) 34(Suppl. 4):S47-S51.
27. GRIDELLI C, GALLO C, SHEPHERD FA et al.: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21(16):3025-3034.
28. KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. (2002) 20(17)3578-3585.
29. SMIT EF, VAN MEERBEECK JP, LIANES P et al.: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J. Clin. Oncol. (2003) 21(21):3909-3917.
30. GRIDELLI C: The ELVIS trial: a Phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist (2001) 6(Suppl. 1):4-7.
31. GRIDELLI C, PERRONE F, GALLO C et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl Cancer Inst. (2003) 95(5):362-372.
32. FRASCI G, LORUSSO V, PANZA N et al.: Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer (2001) 34(Suppl. 4):S65-S69.
33. LANGER CJ, MANOLA J, BERNARDO P et al.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. (2002) 94(3):173-181.
34. LANGER C, VANGEL M, SCHILLER J: Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (< 70 yrs). Lung Cancer (2003):S17.
35. GRIDELLI C, ARDIZZONI A, LE CHEVALIER T et al.: Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. (2004) 15(3):419-426.
36. LANGER C, STEPHENSEN P, SCHILLER J: ECOG 1599: Randomized phase II trial of paclitaxel-carboplatin or gemcitabine-cisplatin in PS2 patients with advanced NSCLC. Lung Cancer (2003) 41(Suppl. 2):S18.
37. KOSMIDIS PA, DIMOPOULOS MA, SYRIGOS C et al. Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group. Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):7058.
38. SANDBACH JF, WEISSMAN C, BROOKER R, ILEGBODU D, ASMAR L: A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age < 65 and performance status 2. Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):7122.
39. COMELLA P, FRASCI G, CARNICELLI P et al.: Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br. J. Cancer (2004) 91(3):489-497.
40. HESKETH PJ, CHANSKY K, LAU DH, CROWLEY J, GANDARA DR: Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027). Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):7056.
41. SWEENEY CJ, ZHU J, SANDLER AB et al.: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer (2001) 92(10):2639-2647.
42. SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (2000) 18(10):2095-2103.
43. FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. (2000) 18(12):2354-2362.
44. HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22(9):1589-1597.
45. CLEGG A, SCOTT DA, HEWITSON P, SIDHU M, WAUGH N: Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax (2002) 57(1):20-28.
46. MCKENDRICK J, BOTWOOD N, ARISTEDES M: Economic evaluation of Gemzar and best supportive care relative to best supportive care alone in the treatment of non-small cell lung cancer in the UK. Value Health (2001) 4:86.
47. DRANITSARIS G, COTTRELL W, EVANS WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr. Opin. Oncol. (2002) 14(4):375-383.
48. LEES M, ARISTIDES M, MANIADAKIS N et al.: Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics (2002) 20(5):325-337.
49. HILLNER BE, SMITH TJ: Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer. Semin. Oncol. (1996) 23(2 Suppl. 5):25-30.
50. SCHILLER J, TILDEN D, ARISTIDES M et al.: Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer (2004) 43(1):101-112.